請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43530完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李公哲(Kung-Cheh Li) | |
| dc.contributor.author | Yu-Tzu Tung | en |
| dc.contributor.author | 董育慈 | zh_TW |
| dc.date.accessioned | 2021-06-15T02:22:56Z | - |
| dc.date.available | 2012-08-19 | |
| dc.date.copyright | 2009-08-19 | |
| dc.date.issued | 2009 | |
| dc.date.submitted | 2009-08-18 | |
| dc.identifier.citation | ASCE, 1992. Design of municipal wastewater treatment plants. Water environment federation.
Baronti, C., Curini, R., D'Ascenzo, G., Di Corcia, A., Gentili, A., Samperi, R., 2000. Monitoring Natural and Synthetic Estrogens at Activated Sludge Sewage Treatment Plants and in a Receiving River Water. Environmental Science & Technology 34, 5059-5066. Bhat, A., Kumar, A., 2008. Application of the Crystal Ball (R) software for uncertainty and sensitivity analyses for predicted concentration and risk levels. Environ. Prog. 27, 289-294. Brion, F., Tyler, C.R., Palazzi, X., Laillet, B., Porcher, J.M., Garric, J., Flammarion, P., 2004. Impacts of 17 beta-estradiol, including environmentally relevant concentrations, on reproduction after exposure during embryo-larval-, juvenile- and adult-life stages in zebrafish (Danio rerio). Aquat. Toxicol. 68, 193-217. Brouwer, R., De Blois, C., 2008. Integrated modelling of risk and uncertainty underlying the cost and effectiveness of water quality measures. Environmental Modelling & Software 23, 922-937. Carlsson, C., Johansson, A.K., Alvan, G., Bergman, K., Kuhler, T., 2006. Are pharmaceuticals potent environmental pollutants? Part I: Environmental risk assessments of selected active pharmaceutical ingredients. Science of the Total Environment 364, 67-87. Cespedes, R., Petrovic, M., Raldua, D., Saura, U., Pina, B., Lacorte, S., Viana, P., Barcelo, D., 2004. Integrated procedure for determination of endocrine-disrupting activity in surface waters and sediments by use of the biological technique recombinant yeast assay and chemical analysis by LC-ESI-MS. Anal. Bioanal. Chem. 378, 697-708. Chen, C.Y., Wen, T.Y., Wang, G.S., Cheng, H.W., Lin, Y.H., Lien, G.W., 2007. Determining estrogenic steroids in Taipei waters and removal in drinking water treatment using high-flow solid-phase extraction and liquid chromatography/tandem mass spectrometry. Science of the Total Environment 378, 352-365. Clouzot, L., Marrot, B., Doumenq, P., Roche, N., 2008. 17 alpha-ethinylestradiol: An endocrine disrupter of great concern. Analytical methods and removal processes applied to water purification. A review. Environ. Prog. 27, 383-396. Daughton, C.G., 2003a. Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rationale for and avenues toward a green pharmacy. Environmental Health Perspectives 111, 757-774. Daughton, C.G., 2003b. Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. II. Drug disposal, waste reduction, and future directions. Environmental Health Perspectives 111, 775-785. Desbrow, C., Routledge, E.J., Brighty, G.C., Sumpter, J.P., Waldock, M., 1998. Identification of estrogenic chemicals in STW effluent. 1. Chemical fractionation and in vitro biological screening. Environmental Science & Technology 32, 1549-1558. Doerr-MacEwen, N.A., Haight, M.E., 2006. Expert stakeholders' views on the management of human pharmaceuticals in the environment. Environ. Manage. 38, 853-866. Drewes, J.E., Hemming, J., Ladenburger, S.J., Schauer, J., Sonzogni, W., 2005. An assessment of endocrine disrupting activity changes during wastewater treatment through the use of bioassays and chemical measurements. Water Environment Research 77, 12-23. Ferrari, B., Mons, R., Vollat, B., Fraysse, B., Paxeus, N., Lo Giudice, R., Pollio, A., Garric, J., 2004. Environmental risk assessment of six human pharmaceuticals: Are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment? Environmental Toxicology and Chemistry 23, 1344-1354. Filali-Meknassi, Y., Auriol, M., Adams, C.D., Surampalli, R.Y., 2007. Quantification of steroid sex hormones using solid-phase extraction followed by liquid chromatography-mass spectrometry. Water Environment Research 79, 687-696. Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., Hsia, J., Hulley, S., Herd, A., Khan, S., Newby, L.K., Waters, D., Vittinghoff, E., Wenger, N., for the HERS Research Group, 2002. Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA 288, 49-57. Gross-Sorokin, M.Y., Roast, S.D., Brighty, G.C., 2006. Assessment of feminization of male fish in English rivers by the environment agency of England and Wales. Us Dept Health Human Sciences Public Health Science, pp. 147-151. Halling-Sorensen, B., Nielsen, S.N., Lanzky, P.F., Ingerslev, F., Lutzhoft, H.C.H., Jorgensen, S.E., 1998. Occurrence, fate and effects of pharmaceutical substances in the environment - A review. Chemosphere 36, 357-394. Health Care Without Harm, 2008. Beyond take-back: getting drugs out of our water. (http://hcwh-newsletter.ecn.cz/article.shtml?x=2122215), accessed April 2009. Health Care Without Harm Hersh, A.L., Stefanick, M.L., Stafford, R.S., 2004. National Use of Postmenopausal Hormone Therapy: Annual Trends and Response to Recent Evidence. JAMA 291, 47-53. Hubbard, M., 2007. OREGON Pharmaceutical Take Back Stakeholder Group. OREGON Pharmaceutical Take Back Stakeholder Group. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., Vittinghoff, E., Heart, f.t., Estrogen/progestin Replacement Study Research Group, 1998. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. JAMA 280, 605-613. Johnson, A.C., Belfroid, A., Di Corcia, A., 2000. Estimating steroid oestrogen inputs into activated sludge treatment works and observations on their removal from the effluent. Science of the Total Environment 256, 163-173. Jones, O.A.H., Voulvoulis, N., Lester, J.N., 2002. Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Research 36, 5013-5022. Kummerer, K., 2008. Pharmaceuticals in the environment: sources, fate, effects and risks. Springer Berlin Heidelberg. Kuch, H.M., Ballschmiter, K., 2001. Determination of endocrine-disrupting phenolic compounds and estrogens in surface and drinking water by HRGC-(NCI)-MS in the picogram per liter range. Environmental Science & Technology 35, 3201-3206. Lin, A.Y.C., Yu, T.H., Lin, C.F., 2008. Pharmaceutical contamination in residential, industrial, and agricultural waste streams: Risk to aqueous environments in Taiwan. Chemosphere 74, 131-141. Matcalf, Eddy, 1979. Wastewater Engineering, Treatment, disposal, reuse. McGraw-Hill, New York. Matcalf, Eddy, 2003. Wastewater Engineering, Treatment and reuse. McGraw-Hill, New York. Metcalf, Eddy, 1991. Wastewater engineering: Treatment, disposal, reuse. McGraw-Hill, New York. Metcalfe, C.D., Metcalfe, T.L., Kiparissis, Y., Koenig, B.G., Khan, C., Hughes, R.J., Croley, T.R., March, R.E., Potter, T., 2001. Estrogenic potency of chemicals detected in sewage treatment plant effluents as determined by in vivo assays with Japanese medaka (Oryzias latipes). Environmental Toxicology and Chemistry 20, 297-308. Mouatassim-Souali, A., Tamisier-Karolak, S.L., Perdiz, D., Cargouet, M., Levi, Y., 2003. Validation of a quantitative assay using GC/MS for trace determination of free and conjugated estrogens in environmental water samples. J. Sep. Sci. 26, 105-111. Pallottino, S., Sechi, G.M., Zuddas, P., 2005. A DSS for water resources management under uncertainty by scenario analysis. Environmental Modelling & Software 20, 1031-1042. Post Consumer Pharmaceutical Stewardship Association, 2008. Pharmaceutical Annual Report 2007. PCPSA, British Columbia. Rio Declaration, 1992. Report of the United Nations Conference on Environment and Development. (http://www.un.org/cyberschoolbus/peace/earthsummit.htm), accessed June 2009. Routledge, E.J., Sheahan, D., Desbrow, C., Brighty, G.C., Waldock, M., Sumpter, J.P., 1998. Identification of estrogenic chemicals in STW effluent. 2. In vivo responses in trout and roach. Environmental Science & Technology 32, 1559-1565. Rudder, J.d., Wiele, T.V.d., Dhooge, W., Comhaire, F., Verstraete, W., 2004. Advanced water treatment with manganese oxide for the removal of 17[alpha]-ethynylestradiol (EE2). Water Research 38, 184-192. Snyder, S.A., Keith, T.L., Verbrugge, D.A., Snyder, E.M., Gross, T.S., Kannan, K., Giesy, J.P., 1999. Analytical methods for detection of selected estrogenic compounds in aqueous mixtures. Environmental Science & Technology 33, 2814-2820. Ternes, T.A., Stumpf, M., Mueller, J., Haberer, K., Wilken, R.D., Servos, M., 1999. Behavior and occurrence of estrogens in municipal sewage treatment plants - I. Investigations in Germany, Canada and Brazil. Science of the Total Environment 225, 81-90. US EPA, 2006a. Definitions of PBT profiler (http://www.pbtprofiler.net/Details.asp). accessed June 2009. US EPA, 2006b. PBT profiler (http://www.pbtprofiler.net/default.asp). accessed June 2009. Ying, G.-G., Kookana, R.S., Ru, Y.-J., 2002. Occurrence and fate of hormone steroids in the environment. Environment International 28, 545-551. 水利署, 2005. 新店溪之美--< 新店溪簡介 > (http://www.wra.gov.tw/ct.asp?xItem=13799&ctNode=1964&comefrom=lp). accessed May 2009. 主計處, 2009. 台灣地區物價統計. (http://61.60.106.82/pxweb/PXfile/PriceStatistics/PriceStatistics.htm#) accessed June 2009. 住都處, 1998. 台灣省台北近郊汙水下水道建設計畫第二、三期工程通盤檢討評估規劃工作-規劃報告附錄. 林郁真, 2007a. 新興汙染物對環境之汙染現況及研究進展. 台大工程 第96期, 73-82. 林郁真, 2007b. 論環境中之新興污染物. 環境工程會刊 第18卷, 39-55. 林郁真, 蔡家弘, 邱嘉明, 林正芳, 2008. 論述藥物與個人保健用品在環境中之風險評估方法. 環境工程會刊 第19卷, 33-61. 林聖烈, 2005. 淡水河口環流與淡水舌之研究. 水文所. 國立中央大學. 高雄市政府工務局下水道工程處, 1998. 高雄市汙水下水道系統檢討規劃報告. 陳鐶友, 2008. 新店溪中藥物分佈之探討：分析方法之建立及風險評估. 環境工程學研究所. 國立台灣大學. 經建會, 2008. 中華民國臺灣97年至145年人口推計報告. 駱尚廉, 蕭代基, 2007. 環境經濟分析. 曉園出版社有限公司, 台北. 營建署, 2002. 台灣地區家庭污水量及污染量推估研究. 台灣下水道協會. 營建署, 2004. 提升都市污水處理廠營運管理體系合理化之研究. 環保署, 2006. 事業與污水下水道系統水污染防治措施管理及檢測申報辦法. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43530 | - |
| dc.description.abstract | 近年來新興污染物對於環境水體之污染已逐漸受重視，而環境荷爾蒙對生態
所造成之危害也已被確認，基於預防原則，本研究使用歐盟所發表之藥物及個人 保健用品之環境風險評估方法，探討在環境中雌激素於「2005 年基準狀態」、「一 切照舊(BAU)至2020 年狀態」、及以情境分析探討「施行減量策略至2020 年狀態」 時雌激素在環境中之濃度，藉以探討四種藥用雌激素(estrone (E1)、17β‐estradiol (E2)、17α‐ethynylestradiol (EE)及estriol (E3))對於新店溪流域可能造成之危害風險， 及其環境風險商數(risk quotient, RQ)。 2005 年基準狀態主要利用國家衛生研究院之國內健保局藥物統計使用量， 推估雌激素於新店溪之可能殘留濃度，以及偵測到的環境濃度，加以推估二者於 新店溪可能造成之風險；一切照舊至2020 年狀態則利用人口成長率進行推估雌 激素之使用量，並評估其於新店溪之風險；施行減量策略至2020 年狀態則以「從 搖籃到搖籃」所延伸出綠色藥局(green pharmacy)之概念提出四種較可行之減量 策略，分別為：醫療政策改變、回收計畫、污水處理場及混合減量。除了以情境 分析各減量策略對RQ 之削減值，本研究更進一步分析四種減量策略之成本有效 性，以期能提供管理者在對於新興污染物管理上之決策依據。 環境風險評估之結果，2005 年基準狀態及一切照舊至2020 年狀態時，四種 雌激素在新店溪中相加所得之總RQ (ΣRQ)遠大於1，極有可能對環境造成危害； 施行減量策略至2020 年狀態之四種減量策略施行後目標年之ΣRQ 雖仍大於1， RQ 削減率可達5.63‐99.98%不等。各減量策略經成本有效性辨識圖分析之結果發 現，最具成本有效性之結果為同時施行醫療政策改變與回收計畫，可達到41‐65% 之RQ 削減率，惟ΣRQ 仍大於1。然而如能完成大台北地區污水下水道建設，污 水經八里污水處理場二級處理後海洋放流，RQ 削減率可達到99.99%，且ΣRQ 可降至1 以下。 | zh_TW |
| dc.description.abstract | In recent years, the pollution of emerging contaminants is concerned, and the harmfulness of environmental hormones is identified. In this research the environmental risk assessment of pharmaceuticals and personal care products (PPCPs) which is published by European Union is used to discuss three situations of estrogens environmental concentrations in the Sin-Dian River. The three situations are “baseline situation in 2005,” “business-as-usual (BAU) situation to 2020,” and “mitigative situation to 2020” discussed by scenario analysis. The risk quotient (RQ) of four pharmaceutical estrogens, estrone (E1), 17b-estradiol (E2), 17a-ethynylestradiol (EE), and estriol (E3), are discussed.
In the baseline situation in 2005, the risks of the medical statistic data of Bureau of National Health Insurance from National Health Research Institutes to estimate the predicted environmental concentration (PEC) and measured environmental concentration (MEC) of estrogens are estimated and compared; in the BAU situation to 2020, the increasing PECs and risks of estrogen by population growth rate are estimated. In the mitigative situation to 2020, four probable mitigative strategies, medical policy, take-back program, wastewater treatment plant, and hybrid, are brought up from the “green pharmacy” of cradle-to-cradle. The cost-effectiveness of four mitigative strategies is also analyzed. The ΣRQs of baseline situation in 2005 and BAU situation to 2020 are larger than 1, and it is possible to be harmful in the environment. Although theΣRQs of mitigative situation to 2020 are larger than 1, the reducing rates are from 5.63-99.98%. The most cost-effectiveness result from the identification diagram for cost-effectiveness analysis is the implementation of both medical policy and take-back program, and theΣRQs are larger than 1 and reducing rates are from 41-65%. If the wastewater is treated by secondary treatment of Bali Wastewater Treatment Plant through the Taipei area sewage system, the reducing rate of RQs, which are lower than 1, can achieve to 99.99%. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T02:22:56Z (GMT). No. of bitstreams: 1 ntu-98-R96541107-1.pdf: 2830757 bytes, checksum: ceef93f481fe8e3440493bd1aaf9db18 (MD5) Previous issue date: 2009 | en |
| dc.description.tableofcontents | 謝誌
摘要 Abstract 目錄 i 圖目錄 v 表目錄 vi 第一章 緒論 1 1.1 研究緣起 1 1.2 研究目的 3 1.3 研究架構 4 第二章 文獻回顧 6 2.1 雌激素基本資料 6 2.1.1 雌激素的用途 6 2.1.2 雌激素的特性 7 2.1.3雌激素的遷移與宿命 12 2.1.4 雌激素之工程去除技術 14 2.2 新店溪流域基本資料 15 2.3 環境風險評估 15 2.4情境分析 17 2.5 不確定性分析 18 2.6 成本有效性分析 18 第三章 研究方法 20 3.1 新店溪流域及雌激素資料 20 3.1.1 新店溪流域背景資料 20 3.1.2 新店溪流域雌激素資料 22 3.2 環境風險評估流程 23 3.2.1 環境風險評估架構 23 3.2.2 環境風險評估情境設定 26 3.3 新店溪流域情境分析架構 27 3.3.1 2005年基準狀態 27 3.3.2 一切照舊至2020年狀態 28 3.3.3 施行減量策略至2020年狀態 28 3.3 不確定性分析 32 3.4 成本有效性分析 34 第四章 結果與討論 36 4.1 環境風險評估 36 4.1.1 2005年基準狀態 36 4.1.2 一切照舊(BAU)至2020年狀態 38 4.1.3 施行減量策略至2020年狀態 39 4.2 不確定性分析 45 4.3 施行減量策略至2020年狀態之成本有效性分析 52 4.3.1 情境一：醫療政策改變 Medical Policy 52 4.3.2 情境二：回收計畫 Take-back Program 52 4.3.3 情境三：污水處理廠 Wastewater Treatment Plant 53 4.3.4 情境四：混合減量 Hybrid mitigation 54 4.3.5 成本有效性分析 55 第五章 結論與建議 60 5.1 結論 60 5.2 建議 63 參考文獻 64 附錄一 70 附錄二 71 | |
| dc.language.iso | zh-TW | |
| dc.subject | 成本有效性分析 | zh_TW |
| dc.subject | 雌激素 | zh_TW |
| dc.subject | 環境風險評估 | zh_TW |
| dc.subject | 風險商數 | zh_TW |
| dc.subject | 情境分析 | zh_TW |
| dc.subject | scenario analysis | en |
| dc.subject | environmental risk assessment | en |
| dc.subject | estrogen | en |
| dc.subject | cost-effectiveness analysis | en |
| dc.subject | risk quotient | en |
| dc.title | 雌激素在新店溪流域之環境風險評估與減量情境分析 | zh_TW |
| dc.title | Environmental Risk Assessment and Mitigative Scenario Analysis of Estrogens in Sin-Dian River | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 97-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 林郁真(Angela Yu-Chen Lin) | |
| dc.contributor.oralexamcommittee | 吳焜裕 | |
| dc.subject.keyword | 雌激素,環境風險評估,風險商數,情境分析,成本有效性分析, | zh_TW |
| dc.subject.keyword | estrogen,environmental risk assessment,risk quotient,scenario analysis,cost-effectiveness analysis, | en |
| dc.relation.page | 77 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2009-08-18 | |
| dc.contributor.author-college | 工學院 | zh_TW |
| dc.contributor.author-dept | 環境工程學研究所 | zh_TW |
| 顯示於系所單位： | 環境工程學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-98-1.pdf 未授權公開取用 | 2.76 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。